Publications
- One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment2023 | First Faculty of Medicine
- Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA2022 | First Faculty of Medicine, Second Faculty of Medicine
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | First Faculty of Medicine
- The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry2022 | First Faculty of Medicine
- The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis2022 | First Faculty of Medicine
- Baricitinib in the treatment of rheumatoid arthritis in routine clinical practice - results from the Czech National ATTRA Registry2021 | Central Library of Charles University, First Faculty of Medicine
- Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration2021 | First Faculty of Medicine
- How biological treatment affects the ability to work in patients with axial spondyloarthritis - results from ATTRA, the Czech national registry2021 | First Faculty of Medicine
- Gender difference in disease severity and treatment outcomes among patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) starting treatment with targeted therapies in the Czech Republic - analysis from the nation-wide ATTRA registry of biological therapy2021 | First Faculty of Medicine
- Gender difference in disease severity and treatment outcomes among patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) treated for one year with certolizumab pegol - analysis from the nationwide ATTRA registry of biological therapy2021 | First Faculty of Medicine
Loading network view...